Comparison of multiple vaccine vectors in a single heterologous prime-boost trial

被引:41
作者
Barefoot, Brice [1 ]
Thornburg, Natalie J. [2 ]
Barouch, Daniel H. [3 ]
Yu, Jae-sung [1 ]
Sample, Christopher [1 ]
Johnston, Robert E. [2 ]
Liao, Hua Xin [1 ]
Kepler, Thomas B. [4 ]
Haynes, Barton F. [1 ]
Ramsburg, Elizabeth [1 ]
机构
[1] Duke Univ, Med Ctr, Sch Med, Duke Human Vaccine Inst, Durham, NC 27710 USA
[2] Univ N Carolina, Carolina Vaccine Inst, Chapel Hill, NC 27599 USA
[3] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02115 USA
[4] Duke Univ, Ctr Computat Immunol, Dept Biostat & Bioinformat, Durham, NC 27710 USA
基金
美国国家卫生研究院;
关键词
Vaccine; Viral vector; Poxvirus;
D O I
10.1016/j.vaccine.2008.09.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The prevention of infectious disease via prophylactic immunization is a mainstay of global public health efforts. Vaccine design Would be facilitated by a better understanding of the type and durability of immune responses generated by different vaccine vectors. We report here the results of a comparative immunogenicity trial of six different vaccine vectors expressing the same insert antigen, cowpox virus 135 (CPXV-B5). Of those vectors tested, recombinant adenovirus (rAd5) was the most immunogenic, inducing the highest titer anti-135 antibodies and conferring protection from sublethal vaccinia virus challenge in mice after a single immunization. We tested select heterologous prime-boost combinations and identified recombinant vesicular stomatitis virus (rVSV) and recombinant Venezuelan equine encephalitis virus replicons (VRP) as the most synergistic regimen. Comparative data Such as those presented here are critical to efforts to generate protective vaccines for emerging infectious diseases as well as for biothreat agents. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6108 / 6118
页数:11
相关论文
共 40 条
[1]   Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R [J].
Aldaz-Carroll, L ;
Whitbeck, JC ;
de Leon, MP ;
Lou, H ;
Hirao, L ;
Isaacs, SN ;
Moss, B ;
Eisenberg, RJ ;
Cohen, GH .
JOURNAL OF VIROLOGY, 2005, 79 (10) :6260-6271
[2]  
André S, 1998, J VIROL, V72, P1497
[3]  
[Anonymous], 1998, Viruses, Plagues, and History
[4]   PREVENTION OR MODIFICATION OF VARICELLA USING ZOSTER IMMUNE PLASMA [J].
BALFOUR, HH ;
GROTH, KE ;
MCCULLOUGH, J ;
KALIS, JM ;
MARKER, SC ;
NESBIT, ME ;
SIMMONS, RL ;
NAJARIAN, JS .
AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1977, 131 (06) :693-696
[5]   Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice [J].
Bernard, KA ;
Klimstra, WB ;
Johnston, RE .
VIROLOGY, 2000, 276 (01) :93-103
[6]   Obligatory requirement for antibody in recovery from a primary poxvirus infection [J].
Chaudhri, Geeta ;
Panchanathan, Vijay ;
Bluethmann, Horst ;
Karupiah, Gunasegaran .
JOURNAL OF VIROLOGY, 2006, 80 (13) :6339-6344
[7]   Synergistic attenuation of vesicular stomatitis virus by combination of specific g gene truncations and N gene translocations [J].
Clarke, David K. ;
Nasar, Farooq ;
Lee, Margaret ;
Johnson, J. Erik ;
Wright, Kevin ;
Calderon, Priscilla ;
Guo, Min ;
Natuk, Robert ;
Cooper, David ;
Hendry, R. Michael ;
Udem, Stephen A. .
JOURNAL OF VIROLOGY, 2007, 81 (04) :2056-2064
[8]   AIDS research - Did Merck's failed HIV vaccine cause harm [J].
Cohen, Jon .
SCIENCE, 2007, 318 (5853) :1048-1049
[9]   Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and G gene truncation reduces neurovirulence and enhances immunogenicity in mice [J].
Cooper, David ;
Wright, Kevin J. ;
Calderon, Priscilla C. ;
Guo, Min ;
Nasar, Farooq ;
Johnson, J. Erik ;
Coleman, John W. ;
Lee, Margaret ;
Kotash, Cheryl ;
Yurgelonis, Irene ;
Natuk, Robert J. ;
Hendry, R. Michael ;
Udem, Stephen A. ;
Clarke, David K. .
JOURNAL OF VIROLOGY, 2008, 82 (01) :207-219
[10]  
Copelovici Y, 1979, Virologie, V30, P171